Literature DB >> 9590117

Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens.

S L Taylor1, A Platt-Higgins, P S Rudland, J H Winstanley, R Barraclough.   

Abstract

The cell-surface receptor tyrosine kinase protein c-erbB-2 is immunocytochemically detected as membrane staining on the surface of cancer cells in 20-30% of cases of breast cancer, and its presence has been associated with poor prognosis for the patient. However, there have been numerous reports of immunocytochemical staining for c-erbB-2 solely in the cytoplasm of some normal and tumour specimens with frequently used anti-sera, and the presence of such staining has been difficult to interpret. It is not known for certain that cytoplasmic c-erbB-2 staining is an artefact of the immunocytochemical procedures used. Thus, mRNA for c-erbB-2 has been quantified in tumours exhibiting only cytoplasmic staining or varying levels of membrane staining using a sensitive, competitive PCR method. Whereas abundant levels of c-erbB-2 mRNA are found in tumours exhibiting membrane staining for c-erbB-2 and these levels correlate with the percentage of tumour cells showing membranous staining for c-erbB-2, the level of c-erbB-2 mRNA in tumours displaying only cytoplasmic staining is no higher than in c-erbB-2-negative specimens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590117     DOI: 10.1002/(sici)1097-0215(19980518)76:4<459::aid-ijc2>3.0.co;2-q

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Raman-Encoded Molecular Imaging with Topically Applied SERS Nanoparticles for Intraoperative Guidance of Lumpectomy.

Authors:  Yu Winston Wang; Nicholas P Reder; Soyoung Kang; Adam K Glaser; Qian Yang; Matthew A Wall; Sara H Javid; Suzanne M Dintzis; Jonathan T C Liu
Journal:  Cancer Res       Date:  2017-06-14       Impact factor: 12.701

2.  Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results.

Authors:  Janina Kulka; Anna-Mária Tôkés; Pál Kaposi-Novák; Nóra Udvarhelyi; Anikó Keller; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2006-12-25       Impact factor: 3.201

Review 3.  Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.

Authors:  P Nagy; A Jenei; S Damjanovich; T M Jovin; J Szölôsi
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

4.  [Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry].

Authors:  M Scheer; W Prange; K Petmecky; P Schirmacher; J E Zöller; A C Kübler
Journal:  Mund Kiefer Gesichtschir       Date:  2003-03-07

5.  Testing for HER2 in Breast Cancer: A Continuing Evolution.

Authors:  Sejal Shah; Beiyun Chen
Journal:  Patholog Res Int       Date:  2010-12-06

6.  Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor.

Authors:  C Bing; S T Russell; E E Beckett; P Collins; S Taylor; R Barraclough; M J Tisdale; G Williams
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

7.  S100A4 (p9Ka) protein in colon carcinoma and liver metastases: association with carcinoma cells and T-lymphocytes.

Authors:  S Taylor; S Herrington; W Prime; P S Rudland; R Barraclough
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

8.  Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer.

Authors:  Erik J Blok; Peter Jk Kuppen; Jeroen Em van Leeuwen; Cornelis Fm Sier
Journal:  Clin Med Insights Oncol       Date:  2013-02-21

9.  Aberrant c-erbB2 expression in cell clusters overlying focally disrupted breast myoepithelial cell layers: a trigger or sign for emergence of more aggressive cell clones?

Authors:  Xichen Zhang; Shahreyar Shar Hashemi; Morvarid Yousefi; Jinsong Ni; Qiuyue Wang; Ling Gao; Pengtao Gong; Chunling Gao; Joy Sheng; Jeffrey Mason; Yan-gao Man
Journal:  Int J Biol Sci       Date:  2008-08-16       Impact factor: 6.580

10.  Identification of mRNAs differentially-expressed between benign and malignant breast tumour cells.

Authors:  D Liu; P S Rudland; D R Sibson; R Barraclough
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.